Oncolytics Biotech Inc.
Stock exchange listing-rule deficiency notice (8-K Item 3.01)
The company reported in a Form 8-K (Item 3.01) filed on 24 Jul 2026 that its stock exchange notified it of not meeting a continued-listing rule. Continued non-compliance can lead to delisting.
More details →Change of auditor (8-K Item 4.01)
The company reported a change of its independent auditor in a Form 8-K (Item 4.01) filed on 08 Jul 2026. Auditor changes are often routine (rotation, cost, mergers), but can follow disagreements over accounting.
More details →Oncolytics Biotech Inc. — Overview & Financial Snapshot
Oncolytics Biotech Inc. (NasdaqCM: ONCY) is a Healthcare company, ranked #6,563 of 6,774 companies globally and #3,807 of 4,000 in United States on PositoAI, with a Positivity Score of -25,296. Its market capitalisation is ₹619.08 Cr ($65.59M), P/E ratio is -1.4 and P/B ratio is -10.64. It currently has 1 active red flag (PosiRed) and 1 yellow flag (PosiYellow, 2/10 points) on record.
For financial statements, ratio trends and score history, Go Deep →